Disclosures: Dr. Barken, Dr. Princen, Dr. Carroll, Shelly Brown, Jordan Stachelski, Dr. Chuang, and Sharat Singh are employees of Prometheus Laboratories Inc. Carol Landers is a stockholder of Prometheus Laboratories Inc. Dr. Rotter and Joanne Stempak have nothing to disclose. Dr. Lichtenstein has received consulting fees and research support from Prometheus Laboratories Inc. Dr. Targan is a founder and stockholder of PrometheusLaboratories Inc. Dr. Dubinsky is a consultant for Prometheus Laboratories Inc. Dr. Silverberg has received consulting fees and research support from Prometheus Laboratories Inc. Writing assistance: Dr. Anthony Stonehouse provided extensive writing support during the development of this article. Dr. Stonehouse is an employee of Watson & Stonehouse Enterprises, LLC.
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior†
Version of Record online: 9 MAR 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 17, Issue 12, pages 2488–2496, December 2011
How to Cite
Lichtenstein, G. R., Targan, S. R., Dubinsky, M. C., Rotter, J. I., Barken, D. M., Princen, F., Carroll, S., Brown, M., Stachelski, J., Chuang, E., Landers, C. J., Stempak, J. M., Singh, S. and Silverberg, M. S. (2011), Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis, 17: 2488–2496. doi: 10.1002/ibd.21661
- Issue online: 9 NOV 2011
- Version of Record online: 9 MAR 2011
- Manuscript Accepted: 15 DEC 2010
- Manuscript Received: 12 NOV 2010
- Prometheus Laboratories Inc, San Diego, CA
- Crohn's disease;
Treatment of Crohn's disease (CD) with biologics may alter disease progression, leading to fewer disease-related complications, but cost and adverse event profiles often limit their effective use. Tools identifying patients at high risk of complications, who would benefit the most from biologics, would be valuable. Previous studies suggest that biomarkers may aid in determining the course of CD. We aimed to determine if combined serologic immune responses and NOD2 genetic markers are associated with CD complications.
In this cross-sectional study, banked blood from well-characterized CD patients (n = 593; mean follow-up: 12 years) from tertiary and community centers was analyzed for six serological biomarkers (ASCA-IgA, ASCA-IgG, anti-OmpC, anti-CBir1, anti-I2, pANCA). In a patient subset (n = 385), NOD2 (SNP8, SNP12, SNP13) genotyping was performed. Complications included stricturing and penetrating disease behaviors. A logistic regression model for the risk of complications over time was constructed and evaluated by cross-validation.
For each serologic marker, complication rates were stratified by quartile. Complication frequency was significantly different across quartiles for each marker (P trend ≤ 0.001). Patients with SNP13 NOD2 risk alleles experienced increased complications versus patients without NOD2 mutations (P ≤ 0.001). A calibration plot of modeled versus observed complication rates demonstrated good agreement (R = 0.973). Performance of the model integrating serologic and genetic markers was demonstrated by area under the receiver operating characteristic curve (AUC = 0.801; 95% confidence interval: 0.757–0.846).
This model combining serologic and NOD2 genetic markers may provide physicians with a tool to assess the probability of patients developing a complication over the course of CD. (Inflamm Bowel Dis 2011;)